LIVMARLI bulk active fine chemical suppliers

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
MuseChem	⤷ Start Trial	I007690	⤷ Start Trial
THE BioTek	⤷ Start Trial	bt-273697	⤷ Start Trial
Smolecule	⤷ Start Trial	S533543	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 29, 2025

Introduction

LIVMARLI (maralixibat), an oral pharmaceutical marketed by Alexion Pharmaceuticals, is approved for the treatment of pruritus associated with Alagille syndrome in pediatric patients. As a potent and specialized drug, LIVMARLI’s efficacy and safety hinge critically on the quality of its active pharmaceutical ingredient (API). The sourcing of API for LIVMARLI involves rigorous validation, quality control, and regulatory compliance to meet strict standards governing pharmaceutical manufacturing.

Overview of LIVMARLI’s API: Maralixibat

Maralixibat, the API for LIVMARLI, is a selective apical sodium-dependent bile acid transporter (ASBT) inhibitor. Its synthesis involves complex organic chemistry processes aimed at ensuring chemical purity, stability, and bioavailability. The API must comply with stringent Good Manufacturing Practices (GMP) and undergo thorough quality assessments before integration into finished pharmaceutical products.

Sources of API for LIVMARLI

1. Original Manufacturer: Alexion Pharmaceuticals

The primary source of maralixibat API is Alexion Pharmaceuticals, which developed and scaled the manufacturing process during clinical development and commercialization phases. As the patent holder and original developer, Alexion maintains an in-house GMP-certified manufacturing plant that supplies the API to ensure strict quality control and regulatory compliance.

2. Contract Manufacturing Organizations (CMOs)

Given the complexities in API synthesis and high GMP standards, pharmaceutical companies often outsource manufacturing to specialized CMOs. These organizations, globally recognized for their API production capabilities, adhere to regulatory standards such as those set by the FDA, EMA, and other authorities. For LIVMARLI, CMOs with expertise in bile acid transporter inhibitors and complex organic synthesis are engaged to ensure supply stability.

Key characteristics of CMO sources include:

Certified GMP compliance.
Proven track record in producing pharmaceutical-grade APIs.
Technical capacity for scale-up and process validation.
Proven quality assurance systems, including stability testing and impurity profiling.

Popular CMO regions include India, China, and Europe, due to their established pharmaceutical manufacturing hubs.

3. Regional API Suppliers

Numerous regional API suppliers, particularly in China and India, have established GMP-compliant facilities capable of producing maralixibat API. Their involvement typically follows stringent qualification processes involving audit visits, batch testing, and documentation review.

India: Several API manufacturers possess FDA and EDQM certifications. Companies like Hikal, Ipca Laboratories, and Glenmark are recognized for complex pharmaceutical APIs.
China: Several domestic API producers, such as Shanghai Fosun Pharmaceutical and Zhejiang Huahai Pharmaceutical, have scaled up biaryl and bile acid derivative APIs.

Supply Chain Considerations

The supply chain integrity is paramount for LIVMARLI due to its clinical sensitivity and the potential impact on patient safety. Sourcing from multiple qualified suppliers minimizes risk of shortages and ensures regulatory compliance.

Dual sourcing: Many pharmaceutical companies employ dual sourcing strategies to mitigate supply disruptions.
Quality audits: Continuous audits and supplier qualification programs ensure ongoing GMP compliance.

Regulatory and Quality Standards in API Sourcing

The API sources for LIVMARLI must meet specific regulatory standards:

GMP Compliance: To ensure consistent quality and safety.
Pharmacopoeial Standards: Such as USP, EP, or JP monographs.
Impurity Profiling: To comply with acceptable limits for process- and product-related impurities.
Stability & Testing: Shelf-life stability testing at manufacturing and supplier sites.

Challenges in API Sourcing for LIVMARLI

Complex Synthesis Routes: Maralixibat’s synthesis involves asymmetric organic reactions and selective functionalization, requiring highly specialized suppliers.
Regulatory Scrutiny: Continuous inspections by authorities such as FDA and EMA are necessary throughout the supply chain.
Supply Chain Disruptions: Geopolitical factors, pandemics, and logistics issues can impact API availability.

Future Outlook

Expanding the API sourcing portfolio is crucial for LIVMARLI’s ongoing commercial success. Emerging new suppliers in Asia with validated GMP processes may become key partners. Additionally, process optimization in synthesis could enable more cost-effective and scalable API production, further enhancing supply stability.

Key Takeaways

The primary API source for LIVMARLI is Alexion’s GMP-certified facilities, complemented by qualified CMOs globally.
Regional API suppliers in India and China play vital roles, provided they meet strict regulatory and quality criteria.
Ensuring supply chain resilience involves dual sourcing, rigorous qualification, and ongoing quality audits.
Regulatory compliance and impurity control are critical in API sourcing for this complex bile acid derivative.
Future API manufacturing enhancements are expected to improve supply stability and reduction of production costs.

FAQs

1. What are the main quality requirements for LIVMARLI’s API?
Maralixibat’s API must meet GMP standards, possess high chemical purity, low impurities, and robust stability profiles, aligned with pharmacopoeial specifications.

2. Are there alternative sources of API outside of Alexion?
Yes, qualified CMOs and regional suppliers in India and China can produce maralixibat API, provided they meet stringent quality and regulatory standards.

3. How does supply chain management impact LIVMARLI manufacturing?
Supply chain robustness ensures consistent API availability, minimizes disruptions, and maintains regulatory compliance, directly affecting product delivery.

4. What role do regional API suppliers play in LIVMARLI’s production?
They serve as significant secondary sources, providing scalability and risk mitigation, especially during supply shortages or high demand periods.

5. What are the future prospects for API sourcing in this therapeutic area?
Emerging suppliers with validated GMP processes and process innovations are likely to diversify and strengthen supply chains for complex APIs like maralixibat.

References

FDA. (2021). Guidance for Industry: Quality Considerations for Active Pharmaceutical Ingredient Manufacturing.
EMA. (2022). Guideline on the chemistry of active ingredients.
Alexion Pharmaceuticals. (2022). LIVMARLI (maralixibat) Prescribing Information.
WHO. (2019). WHO Guidelines on Good Manufacturing Practices.
PharmSource. (2021). Global API Industry Report.

Bulk Pharmaceutical API Sources for LIVMARLI